A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2001
11/15/2001	CA2408293A1 Novel vitronectin receptor antagonists
11/15/2001	CA2408220A1 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408196A1 Sphingosine kinase and uses thereof
11/15/2001	CA2408152A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	CA2408124A1 Transgenically produced decorin
11/15/2001	CA2408010A1 Identification of neural defects associated with the nucleosomal assembly protein 1l2 gene
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407897A1 Molecular antigen arrays and vaccines
11/15/2001	CA2407886A1 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
11/15/2001	CA2407864A1 Lipid metabolism enzymes
11/15/2001	CA2407852A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407817A1 Anthranilamides and their use as pharmaceutical agents
11/15/2001	CA2405968A1 Hydantoin derivatives with affinity for somatostatin receptors
11/14/2001	EP1154019A2 G-protein coupled receptor (HFGAN72X)
11/14/2001	EP1153928A1 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
11/14/2001	EP1153920A1 Quinoline derivatives and quinazoline derivatives
11/14/2001	EP1153612A1 Anticancer agent potentiators
11/14/2001	EP1153129A1 Method of treating restenosis by antisense targeting of c-myc
11/14/2001	EP1153128A1 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
11/14/2001	EP1153125A1 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
11/14/2001	EP1153122A2 Maturation of dendritic cells with immune response modifying compounds
11/14/2001	EP1153024A1 2-amino-6-anilino-purines and their use as medicaments
11/14/2001	EP1153015A1 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases
11/14/2001	EP1153014A2 Beta-alanine derivatives
11/14/2001	EP1152772A2 Liposome composition and method for administration of a radiosensitizer
11/14/2001	EP1152770A1 Small peptides and methods for treatment of asthma and inflammation
11/14/2001	EP1152767A2 Method for producing anti-tumor th1 cells
11/14/2001	EP1152764A1 Compositions and methods for use in targeting vascular destruction
11/14/2001	EP1152761A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
11/14/2001	EP1152758A1 Use of lipoic acid in combination with ascorbic acid in the treatment of cancer
11/14/2001	EP1152750A1 Spontaneously dispersible n-benzoyl staurosporine compositions
11/14/2001	EP1061938B1 Oral compositions at low dosage of cytotoxic proteins
11/14/2001	EP1021437B1 Arylsulfonylimidazolone derivatives as an antitumor agent
11/14/2001	EP0956016A4 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
11/14/2001	EP0815087B1 Trisubstituted phenyl derivatives
11/14/2001	EP0728763B1 Ganglioside gm3 analog having sialic acid residue fluorinated at the 9-position and intermediate therefor
11/14/2001	EP0672041B1 Pharmacologically active pyridine derivatives and processes for the preparation thereof
11/14/2001	EP0652948B1 Development of a vector to target gene expression to the epidermis of transgenic animals
11/14/2001	CN1322251A Mutant human hepatitis B viral strain and uses thepeof
11/14/2001	CN1322246A Restin and methods of use thereof
11/14/2001	CN1322244A Tumor necrosis factor-gamma
11/14/2001	CN1322206A Naphtho- and dihydrobenzo-thiopyhene derivatives as cytotoxic antitumor agents
11/14/2001	CN1322202A Quinazoline derivatives
11/14/2001	CN1322196A Naphthalenecaarboxamides as tachykinin receptor antagonists
11/14/2001	CN1322194A Substituted phenyl derivatives, their preparation and use
11/14/2001	CN1322136A Neuroimmunophilins for selective neuronal radioprotection
11/14/2001	CN1322134A Naphthalenecarboxamides as tachykinin receptor antagonists
11/14/2001	CN1322133A Vitronectin receptor antagonists
11/14/2001	CN1322130A Inhibitors of type 3 3a -hydrosteroid dehydrogenase
11/14/2001	CN1321771A Novel polypeptide-human dihydroorotase 17 and polynucleotide for coding this polypeptide
11/14/2001	CN1321768A Novel polypeptide-human ATP-dependent serine proteolytic enzyme 21 and polynucleotide for coding this polypeptide
11/14/2001	CN1321766A Novel polypeptide-human ATP-dependent serine proteolytic enzyme 13 and polynucleotide for coding this polypeptide
11/14/2001	CN1321763A Novel polypeptide-human phosphatidase 13 and polynucleotide for coding this polypeptide
11/14/2001	CN1321745A Macrophage inflammatory protein -3, -4 and -1 gamma
11/14/2001	CN1321679A Novel polypeptide-human kingle protein 14 and polynucleotide for coding this polypeptide
11/14/2001	CN1321678A Novel polypeptide-human kruppel related DNA bindin 42 and polynucleotide for coding this polypeptide
11/14/2001	CN1321677A Novel polypeptide-human Pax protein 11.9 and polynucleotide for coding this polypeptide
11/14/2001	CN1321676A Novel polypeptide-human NPAT protein 12 and polynucleotide for coding this polypeptide
11/14/2001	CN1321675A Novel polypeptide-human P18 protein 21 and polynucleotide for coding this polypeptide
11/14/2001	CN1321674A Novel polypeptide-human NPAT protein 15 and polynucleotide for coding this polypeptide
11/14/2001	CN1321664A Novel polypeptide-human pax protein 23 and polynucleotide for coding this polypeptide
11/14/2001	CN1321659A Novel polypeptide-human laminin B2 strand 12 and polynucleotide for coding this polypeptide
11/14/2001	CN1321656A Novel polypeptide-human Pax protein 11 and polynucleotide for coding this polypeptide
11/14/2001	CN1321654A Novel polypeptide-human pax protein 11.4 and polynucleotide for coding this polypeptide
11/14/2001	CN1321653A Novel polypeptide-human kruppel related DNA bindin 10 and polynucleotide for coding this polypeptide
11/14/2001	CN1321652A Novel polypeptide-human protein 10 containing gamma-glutamyl transpeptidase signature sequence fragment and polynucleotide for coding this polypeptide
11/14/2001	CN1321645A Novel polypeptide-KIAA0883-44 polynucleotide for coding this polypeptide
11/14/2001	CN1321644A Chiral octahedral Mo-W complexes, their synthesis method and application for preparing anticancer medicine
11/14/2001	CN1321639A Substd. heterocyclic compounds, preparing process thereof and pharmaceutical composition contg them
11/14/2001	CN1321634A Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them
11/14/2001	CN1321509A Compound Chinese medicine prepared by using snake medicine qianshouguanyin for preventing cancer of lung, and method for preparing same
11/14/2001	CN1321508A Chinese medicine for curing gastropathy
11/14/2001	CN1321485A Lintongtie plaster and its preparation method
11/14/2001	CN1321469A Pinctada martensii visceral organs glycoprotein and glycosaminoglycan with tumor-resisting activity and their extraction process
11/14/2001	CN1074671C Medicinal pollen for treating cancer
11/13/2001	US6316648 Purified 5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid; anticarcinogenic and antiproliferative agents
11/13/2001	US6316642 For therapy of osteoporosis and psoriasis, as anticancer agent
11/13/2001	US6316497 For suppressing cell proliferation and neovascularization
11/13/2001	US6316485 1,5-diphenylpyrazole derivatives
11/13/2001	US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001	US6316462 Methods of inducing cancer cell death and tumor regression
11/13/2001	US6316456 Purine derivatives having, in particular, antiproliferative properties, and their biological uses
11/13/2001	US6316455 Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound
11/13/2001	US6316454 Inducing apoptosis and preventing metastases of brain tumor cells
11/13/2001	US6316435 Combination therapy for lymphoproliferative diseases
11/13/2001	US6316429 Enzyme inhibitors modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
11/13/2001	US6316425 Therapeutic agents
11/13/2001	US6316416 Uteroglobin therapy for epithelial cell cancer
11/13/2001	US6316409 Modified ligands of calcium-dependent binding proteins
11/13/2001	US6316259 Antisense inhibition of glycogen synthase kinase 3 alpha expression
11/13/2001	US6316256 Method for protein transfer
11/13/2001	US6316239 HKABY60 kinase family polypeptides
11/13/2001	US6316217 Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same
11/13/2001	US6316214 ETM-775 metabolite of ecteinascidin 743
11/13/2001	US6316208 Methods for determining isolated p27 protein levels and uses thereof
11/13/2001	US6316009 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharamaceutical and cosmetic compositions containing same
11/13/2001	US6316007 Combined physical and immunotherapy for cancer

1 ... 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 ... 2211